​Active compounds found in plants of the Cannabis genus as well as endogenous analogs of these substances, and a myriad of synthetic analogs can influence a wide range of biological processes by engaging G protein-coupled receptors (GPCRs) of the endocannabinoid system.

Alkyl side chain length directly correlates with receptor binding affinity at human cannabinoid receptors. Novel four-carbon and seven-carbon homologs of cannabidiol (CBD) and Δ⁹-THC are reported to have binding activity more potent than that of Δ⁹-THC.

The development of addiction-free medications effective for treating severe pain is a major aim for combating the misuse of prescription opioids. In a continued effort to create safe and more effective opioid alternatives, several novel strategies are being employed.

Although today we still know very little about Cannabis, its powers come from the ability of the chemical constituents to activate and affect the endocannabinoid system (ECS), a homeostatic regulatory system ubiquitous to every living creature on the planet.

A novel lipid naming convention has recently been proposed by Dr. Heather Bradshaw, Associate Professor of Neuroscience at Indiana University Bloomington and the current president of The International Cannabinoid Research Society. Dr. Bradshaw has proposed the term lipoamine to encompass the family of lipids formed by the conjugation of fatty acids to any simple amine such as ethanolamine, monoamine neurotransmitters such as dopamine, taurine, serotonin, and GABA and all amino acids.

As the cannabis industry is now a multibillion-dollar global market and will only continue to grow as more